A one-time $2.125M gene therapy competes with two chronic therapies for the same SMN-deficient patient — and newborn screening now decides the winner at diagnosis.
Spinal muscular atrophy is a monogenic motor-neuron disease: biallelic loss of SMN1, with SMN2 copy number setting severity. Three FDA-approved agents address it by distinct mechanisms and routes. Nusinersen (Spinraza, Biogen), approved December 2016 as the first SMA therapy, is an antisense oligonucleotide that modifies SMN2 splicing and is given by intrathecal injection. Onasemnogene abeparvovec (Zolgensma, Novartis Gene Therapies), approved May 2019 for patients under two years, is a one-time AAV9 gene therapy that replaces SMN1. Risdiplam (Evrysdi, Roche/PTC Therapeutics), approved August 2020 for all ages and types, is a daily oral SMN2 splicing modifier.
The commercial contest turns on two forces. First, modality economics: a single $2.125M gene-therapy infusion competes against therapies billed for life (nusinersen and risdiplam), so payers and clinicians weigh one-time cure-intent against chronic control, with age and SMN2 copy number driving the choice. Second, newborn screening: SMA was added to the federal Recommended Uniform Screening Panel in 2018 and all 50 states screen as of 2023, moving roughly 300 new diagnoses a year into a pre-symptomatic window where treatment, gene therapy in particular, produces near-normal motor development. The battleground has shifted from rescuing symptomatic infants to treating identified-but-asymptomatic newborns.
FDA-approved spinal muscular atrophy therapies — United States, 2026
| Drug (Brand / INN) | Mechanism | Route & Dosing | Company | US Approval | Key Trial Result |
|---|---|---|---|---|---|
| Spinraza (nusinersen) | SMN2 splicing modifier (antisense oligonucleotide) | Intrathecal; loading + maintenance (chronic) | Biogen | Dec 2016 | ENDEAR: motor-milestone responders 41% vs 0% control |
| Zolgensma (onasemnogene abeparvovec) | AAV9 SMN1 gene replacement | One-time IV infusion (age <2) | Novartis Gene Therapies | May 2019 | STR1VE: 91% event-free survival at 14 months; 59% sat independently |
| Evrysdi (risdiplam) | SMN2 splicing modifier | Oral, once daily (chronic; all ages/types) | Roche / PTC Therapeutics | Aug 2020 | FIREFISH: motor-milestone gains and improved survival vs Type 1 natural history |
Sources: FDA Drugs@FDA (approval status and dates); ENDEAR, NEJM 2017 (PMID 29091570); STR1VE, Lancet Neurology 2021 (PMID 33743238); FIREFISH, NEJM 2021 (PMID 33626251). Onasemnogene WAC per Novartis (2019).
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Intrathecal ASO vs one-time gene therapy vs daily oral — mechanism and administration • Efficacy across ENDEAR, CHERISH, STR1VE, FIREFISH and SUNFISH • Type 1–4 and SMN2 copy number as the treatment-selection axis • Where age <2 and pre-symptomatic status gate gene-therapy eligibility
Delivers
- • RUSP addition and 50-state screening timeline • Pre-symptomatic vs symptomatic patient segmentation • Gene-therapy positioning in NBS-identified infants under two • Chronic-therapy positioning in older and symptomatic patients
Delivers
- • $2.125M one-time vs cumulative nusinersen and risdiplam cost over 10 years • Outcomes-based contract structures for gene therapy • Part B (intrathecal) vs Part D (oral) benefit routing • Step-edit and sequencing dynamics in older patients
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Nusinersen (Biogen, 2016), onasemnogene abeparvovec (Novartis, 2019) and risdiplam (Roche/PTC, 2020) — three mechanisms competing for the same SMN target
- Why route and dosing, intrathecal, one-time IV, or daily oral, split prescribing by patient age and SMN2 copy number
- ENDEAR: 41% of nusinersen-treated infants reached motor milestones vs 0% on control, the pivotal data behind the December 2016 approval
- STR1VE and FIREFISH results behind onasemnogene abeparvovec and risdiplam: 91% event-free survival at 14 months and motor-milestone gains vs Type 1 natural history
- SMA joined the federal RUSP in 2018; all 50 states now screen newborns, routing roughly 300 new diagnoses a year into a pre-symptomatic window
- Why pre-symptomatic identification shifts the competitive battleground from rescuing symptomatic infants to treating newborns before onset
- The $2.125M one-time onasemnogene abeparvovec WAC weighed against the cumulative cost of lifetime nusinersen or risdiplam dosing
- How outcomes-based contract structures let payers hedge the one-time gene-therapy bet against long-term efficacy durability
- Why intrathecal nusinersen routes through the medical benefit (Part B) while oral risdiplam routes through the pharmacy benefit (Part D)
- Step-edit and sequencing dynamics that shape treatment choice in older, already-symptomatic patients outside the gene-therapy eligibility window
- The bar next-generation mechanisms must clear: 41% motor-milestone response for nusinersen, 91% event-free survival for onasemnogene, oral dosing for risdiplam
- Where the under-two gene-therapy eligibility gate and lifetime chronic-dosing burden leave room for new SMA treatment approaches
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Spinal Muscular Atrophy Competitive Intelligence sources: FDA Drugs@FDA (approval status and dates), primary trial publications in the New England Journal of Medicine and Lancet Neurology (ENDEAR, STR1VE, FIREFISH), ClinicalTrials.gov registrations, the federal Recommended Uniform Screening Panel (RUSP) and CureSMA newborn-screening tracking, and Novartis, Biogen and Roche pricing disclosures.
- Nusinersen ENDEAR motor-milestone result verified against NEJM 2017 (PMID 29091570)
- Onasemnogene STR1VE survival result verified against Lancet Neurology 2021 (PMID 33743238)
- Risdiplam FIREFISH Type 1 result verified against NEJM 2021 (PMID 33626251)
- Approval status and indications verified against FDA Drugs@FDA
Frequently asked questions
Commission this brief
AXLRx delivers US spinal muscular atrophy competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.